Zobrazeno 1 - 10
of 13
pro vyhledávání: '"SHAN-BING WANG"'
Publikováno v:
Cancer Medicine, Vol 8, Iss 17, Pp 7219-7226 (2019)
Abstract Background The purpose of the current study was to evaluate whether radiation dose‐volume metrics to technetium‐99m (99mTc) sulfur colloid single‐photon emission tomography (SPET)‐defined active bone marrow (ABM) subregions can more
Externí odkaz:
https://doaj.org/article/67423cad3a6c47899c1b7d0316a40ddc
Autor:
Yue Ren MSc, Shan-Bing Wang MSc, Lin Zhou PhD, Si-Qiao Liu MSc, Lei-Ya Du MSc, Ting Li MSc, Mao-Qiong Jiang BSc, Kai-Jian Lei MSc, Bang-Xian Tan MSc, Yu-Ming Jia BSc
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Background: Symptomatic multiple brain metastases with peritumoral brain edema (PTBE) occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or are resistant to epidermal growth factor tyrosine kinase (EGFR-TKI) are oft
Externí odkaz:
https://doaj.org/article/a818e40f26e14d65a872be7b03ec7023
Publikováno v:
Journal of Surgical Oncology. :1-3
Neoplastic fever, a common symptom of tumors, can be mainly controlled by nonsteroidal antiinflammatories (NSAIDs) and corticosteroids. However, there is no standard treatment guideline for refractory neoplastic fever, which cannot be controlled by t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae75dc13e40bf1efb588ad3fd85b9622
https://doi.org/10.31487/j.jso.2020.06.06
https://doi.org/10.31487/j.jso.2020.06.06
Autor:
Shan-Bing Wang, Yu-Ming Jia, Yue Ren, Mao-Qiong Jiang, Lin Zhou, Lei-Ya Du, Ting Li, Kai-Jian Lei, Bangxian Tan, Si-Qiao Liu
Publikováno v:
Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment, Vol 20 (2021)
Technology in Cancer Research & Treatment, Vol 20 (2021)
Background: Symptomatic multiple brain metastases with peritumoral brain edema (PTBE) occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or are resistant to epidermal growth factor tyrosine kinase (EGFR-TKI) are oft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::165c77c686e80e958ab2cd7bae067ef8
https://pubmed.ncbi.nlm.nih.gov/33955301
https://pubmed.ncbi.nlm.nih.gov/33955301
Publikováno v:
Journal of Clinical Oncology. 40:5527-5527
5527 Background: Acute haematologic toxicity is the most common side effect of chemoradiotherapy in patients with locally advanced cervical cancer.We are aim to test the efficacy of defined active bone marrow sparing volumetric-modulated arc therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1695687123d46fafd60bb0d4a0948e10
https://doi.org/10.1200/jco.2022.40.16_suppl.5527
https://doi.org/10.1200/jco.2022.40.16_suppl.5527
Publikováno v:
Dermatologic Therapy. 33
Hand-foot syndrome (HFS) is a specific cutaneous toxicity caused by a variety of antitumor drugs. The most common drugs include capecitabine, pegylated liposomal doxorubicin and fluorouracil (PLD), tyrosine kinase inhibitor. It is a dose-limiting cut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aabebd882a88ca4e6861e579103048a
https://doi.org/10.1111/dth.13241
https://doi.org/10.1111/dth.13241
Publikováno v:
Medicine
Evidence indicates that type 2 diabetes may stimulate the initiation and progression of several types of cancer. Metformin, a drug most commonly used to treat type 2 diabetes, may inhibit cancer cell growth and reduce the risk of cancer. However, evi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59697d49e6875551ca3b6e5708a11720
https://pubmed.ncbi.nlm.nih.gov/28723808
https://pubmed.ncbi.nlm.nih.gov/28723808
Publikováno v:
Medicine. 98:e14182
Rationale:The potential efficacy of apatinib in patients with advanced triple-negative breast cancer (TNBC) has been observed in a previous phase II clinical study. However, there is no study to evaluate its efficacy and safety in TNBC patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec12632e74e774b2d66a35640f8d05e3
https://doi.org/10.1097/md.0000000000014182
https://doi.org/10.1097/md.0000000000014182
Publikováno v:
Oncology Letters. Aug2015, Vol. 10 Issue 2, p954-956. 3p.
Inhibitors of epidermal growth factor receptor (EGFR), including tyrosine kinase inhibitors (TKIs), present significant clinical benefits in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with an EGFR mutation. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0b83ab2584dd0c2bec4171d87d2f1b2
https://europepmc.org/articles/PMC4509027/
https://europepmc.org/articles/PMC4509027/
